国家医保政策“精准护航” 儿童用药迎来利好

Group 1 - The National Healthcare Security Administration has been actively enhancing children's medication security through various innovative measures, with the recent approval of the innovative drug Zeli Mei (Benvimod Cream) for eczema, which is expected to benefit millions of children suffering from atopic dermatitis [1][2] - The inclusion of Zeli Mei in the initial review is a recognition of its innovative value and exemplifies the national healthcare policy's commitment to safeguarding children's health [2] - The drug Zeli Mei, approved for children over 2 years old, fills a significant gap in the global market for pediatric eczema treatments, offering a safer alternative to traditional steroid medications [1] Group 2 - The approval of Zeli Mei aligns with the "Healthy China 2030" strategy, indicating that the construction of the children's medication security system in China will see more breakthrough developments [2] - The company behind Zeli Mei expressed commitment to collaborating with national healthcare policies to expedite the availability of the product to families across the country [2]